“A Future in Biomedicine”, an initiative to promote scientific vocation among university students
«Spark», a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
A further step towards light-controlled drugs
Olga Torres Foundation grants funding to a project on colon cancer at IRB Barcelona
Last year, a group of scientists at the Insititute for Bioengineering of Catalonia (IBEC), IRB Barcelona and the University of Barcelona a
Postdoctoral researcher Raquel Batlle, member of the Signalling and Cell Cycle Laboratory led by Ángel Rodríguez Nebreda at IRB Barcelona, will conduct a project called “Contribution of p38 MAPK si
“La Vanguardia”, together with other national and international media outlets, has published a news story about “Spark”, a project launched by a public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off located at PCB. IRB Barcelona, CRG, the University of the Bask Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project.
Wall Street International Magazine
The Wall Street International Magazine has published in an article on the development of compounds with therapeutic purposes capable of crossing the blood-brain barrier, which protects the brain from infection.
“Magazine” puts the spotlight on how science is funded in Spain. It gathers the opinions of prominent figures in research, including those of Joan Guinovart, Roger Gomis and Elena Sancho, from IRB Barcelona, who draw attention to the relevance of research as an economic driver.
«98% of the potential therapeutic molecules against diseases of the central nervous system cannot cross the blood-brain barrier. We develop peptides with the capacity to open the doors of the barrier and act as shuttles when attached to a therapeutic molecule.»
«Our study highlights the complexity of p38 functions, both in cancer and in the maintenance of normal tissues. It shows why an inhibitor of this molecule could effectively have undesirable side effects. But these do not exclude it from being a target against cancer.»
More on this news here.
«Controlling a biological process from outside is the future of chemistry and opens up promising roads for advancements in pharmacological research.»
More info on this news here.
Felice Alessio Bava
ex PhD student in the Translational Control of Cell Cycle and Differentiation Lab
«We suspected that CPEB1, a protein involved in regulating mRNA translation in the cytoplasm, might also be active in the nucleus and play a role in controlling pre-mRNA processing. We discovered that it affects the alternative generation in the mature mRNA of the 3'-UTR, regions where most of the elements regulating translation in time and space are located.»
More info about this news here.
Quick facts about IRB
IRB Barcelona has been awarded the "HR Excellence in Research" logo. This recognition reflects the commitment of the Institute to continuously improving its human resources policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The award confirms the efforts of the Institute to ensure fair and transparent recruitment and appraisal procedures. Click here for more information.
IRB Barcelona is home to nearly 450 research, technical and support staff from 35 countries who share the common goal of contributing to the advancement of the biomedical sciences through investigator–driven research, and improving quality of life by applying advances in this field.
The convergence of biology, chemistry, and structural and computational biology is unique at IRB Barcelona and opens a strategic window to gain insight into basic molecular processes in health and disease.
Research is conducted by 23 groups organized into 5 interdisciplinary programmes. Each programme includes a diverse faculty of researchers with overlapping scientific interests. The research areas have been structured to be highly interactive, fostering multidisciplinarity by combining modern molecular biology, classical genetics, biochemistry, structural biology, bioinformatics, systems biology, advanced microscopy, and genomic and proteomic approaches.